Genetics of alpha 1-antitrypsin deficiency in relation to neonatal liver disease

S Povey1

  • 1MRC Human Biochemical Genetics Unit, Galton Laboratory, University College London, U.K.

Molecular Biology & Medicine
|April 1, 1990
PubMed

Insights

Alpha-1-antitrypsin (AAT) deficiency (PIZZ genotype) is a common genetic disorder in infants, often leading to neonatal hepatitis or cirrhosis. The exact cause of liver damage in PIZZ infants remains unclear, hindering effective treatment and genetic counseling.

Area of Science:

  • Genetics
  • Hepatology
  • Immunology

Background:

  • Alpha-1-antitrypsin (AAT) deficiency, specifically the PIZZ genotype, is a prevalent single-gene defect in newborns of European descent.
  • Approximately 17% of affected infants present with neonatal hepatitis, and a subset develop severe liver disease, including cirrhosis, potentially leading to liver transplant or childhood mortality.
  • The precise pathogenesis of liver disease in AAT deficiency is not fully understood, complicating treatment and genetic counseling strategies.

Purpose of the Study:

  • To investigate the genetic and environmental factors contributing to liver disease severity in infants with alpha-1-antitrypsin deficiency (PIZZ genotype).
  • To explore potential associations between specific genetic markers, environmental influences, and the clinical course of liver disease in affected newborns.
  • To identify reliable methods for predicting disease severity and improving diagnostic approaches for AAT deficiency.

Main Methods:

  • Genotyping analysis of the alpha-1-antitrypsin (PI) locus in infants with neonatal disease.
  • Correlation studies examining the severity of liver disease in relation to PIZZ genotype and potential familial or environmental factors.
  • Investigation of potential associations with HLA class II antigens and the impact of breastfeeding.

Main Results:

  • The homozygous PIZZ genotype is the only confirmed genetic association with neonatal liver disease in AAT deficiency.
  • The mutation leads to alpha-1-antitrypsin (AAT) protein accumulation within hepatocytes, but additional unidentified factors determine disease severity.
  • Evidence suggests potential familial influences on disease severity and a possible protective effect of breastfeeding; HLA class II DR3 antigen positivity is more frequent in affected children.

Conclusions:

  • While the PIZZ genotype is necessary for severe liver disease in AAT deficiency, other unidentified factors, possibly immune-related or familial, play a crucial role in disease progression.
  • Current methods cannot reliably predict the severity of liver disease in PIZZ infants, impacting parental decisions regarding future pregnancies.
  • Accurate diagnosis of the PIZZ genotype via DNA analysis is essential for early identification and management, though therapeutic strategies like AAT replacement require further investigation.

Related Concept Videos

Lethal Alleles02:41

Lethal Alleles

Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...